中国商环
Shang Ring

改变了传统的男性包皮环切手术概念


一种更加安全、有效和可接受的男性包皮环切器械和手术方法


欢迎您访问中国商环信息网站!
www.ShangRing.cn
__________________________________________________________________________________________________________________
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
在肯尼亚基苏木青年男性中行男性包皮环切预防艾滋病毒感染:一项随机对照试验
Lancet. 2007 Feb 24;369(9562):643-56.

Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.

Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CF, Campbell RT, Ndinya-Achola JO.

Source

Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL 60612, USA. rcbailey@uic.edu

Abstract

BACKGROUND:

Male circumcision could provide substantial protection against acquisition of HIV-1 infection. Our aim was to determine whether male circumcision had a protective effect against HIV infection, and to assess safety and changes in sexual behaviour related to this intervention.

METHODS:

We did a randomised controlled trial of 2784 men aged 18-24 years in Kisumu, Kenya. Men were randomly assigned to an intervention group (circumcision; n=1391) or a control group (delayed circumcision, 1393), and assessed by HIV testing, medical examinations, and behavioural interviews during follow-ups at 1, 3, 6, 12, 18, and 24 months. HIV seroincidence was estimated in an intention-to-treat analysis. This trial is registered with ClinicalTrials.gov, with the number NCT00059371.

FINDINGS:

The trial was stopped early on December 12, 2006, after a third interim analysis reviewed by the data and safety monitoring board. The median length of follow-up was 24 months. Follow-up for HIV status was incomplete for 240 (8.6%) participants. 22 men in the intervention group and 47 in the control group had tested positive for HIV when the study was stopped. The 2-year HIV incidence was 2.1% (95% CI 1.2-3.0) in the circumcision group and 4.2% (3.0-5.4) in the control group (p=0.0065); the relative risk of HIV infection in circumcised men was 0.47 (0.28-0.78), which corresponds to a reduction in the risk of acquiring an HIV infection of 53% (22-72). Adjusting for non-adherence to treatment and excluding four men found to be seropositive at enrollment, the protective effect of circumcision was 60% (32-77). Adverse events related to the intervention (21 events in 1.5% of those circumcised) resolved quickly. No behavioural risk compensation after circumcision was observed.

INTERPRETATION:

Male circumcision significantly reduces the risk of HIV acquisition in young men in Africa. Where appropriate, voluntary, safe, and affordable circumcision services should be integrated with other HIV preventive interventions and provided as expeditiously as possible.

Comment in

  • Eur Urol. 2007 Aug;52(2):605-6.
  • Evid Based Med. 2007 Aug;12(4):104.
  • Lancet. 2007 Feb 24;369(9562):617-9.
  • Lancet. 2007 May 12;369(9573):1598; author reply 1598-9.
  • Lancet. 2007 May 12;369(9573):1597; author reply 1598-9.
  • Lancet. 2007 May 12;369(9573):1597-8; author reply 1598-9.
  • Lancet. 2007 May 12;369(9573):1597; author reply 1598-9.
PMID: 17321310 PubMed - indexed for MEDLINE]

Full text PDF
 
 
__________________________________________________________________________________________________________________

| 主 页 | 文献下载 | 相关新闻 | 版权声明 | 联系我们 |

Shang RingTM 和 商环TM芜湖圣大医疗器械技术有限公司的注册商标

网站设计与维护:南京埃利希生物技术有限责任公司 版权所有

苏ICP备11018658号